Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE. - Wikidata - wikimedia - TriplyDB

Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE.

Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE.

http://www.wikidata.org/entity/Q33870336

about

Vaccines to combat the neglected tropical diseases.Cross-Protective Immunity to Leishmania amazonensis is Mediated by CD4+ and CD8+ Epitopes of Leishmania donovani Nucleoside Hydrolase Terminal Domains Genetically modified organisms and visceral leishmaniasis Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease.Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi Evaluation of a Novel Herbal Immunomodulator Drug (IMOD) in Treatment of Experimental Canine Visceral leishmaniasis The immunopathology of canine vector-borne diseases.Vaccines for canine leishmaniasis.Assessment of the Effects of a Novel Herbal Immunomodulator Drug (IMOD) on Cytokine Profiles in Experimental Canine Visceral Leishmaniasis: a Preliminary Survey Use of a recombinant cysteine proteinase from Leishmania (Leishmania) infantum chagasi for the Immunotherapy of canine visceral Leishmaniasis KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis Development of Vaccines against Visceral Leishmaniasis Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis.The development and clinical evaluation of second-generation leishmaniasis vaccines.Evaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL/6 mice Development of Leishmania vaccines: predicting the future from past and present experience.Comparative Analysis of Cellular Immune Responses in Treated Leishmania Patients and Hamsters against Recombinant Th1 Stimulatory Proteins of Leishmania donovani.A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden.Use of defined TLR ligands as adjuvants within human vaccines.New vaccines needed for pathogens infecting animals and humans: One Health.DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control.Leishmaniasis and various immunotherapeutic approaches.Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.Protective immunity using MPL-A and autoclaved Leishmania donovani as adjuvants along with a cocktail vaccine in murine model of visceral leishmaniasis.Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.Alternative to Chemotherapy-The Unmet Demand against Leishmaniasis.

P2860

Q30425005-9713093A-7D24-4E68-A58C-E96D2030264D Q33579979-0D43692F-86C9-4D8D-BEB4-27AA15D89972 Q33647026-53350348-4701-48C8-B350-054CF809FDC2 Q33749424-DC04E39D-958A-491A-8CE8-547DD96DF831 Q34076804-D6FED433-F7D8-4439-925C-2A027F340E0B Q34235741-0676C2DF-4117-4E45-8CD9-C964CF48C989 Q34515998-A8F857DB-1910-4A98-9748-8F44B935CEF9 Q34961388-38F5EA67-9806-4BC8-B811-44DA679FB889 Q34979934-59C37CDE-2D27-4CAB-BC12-AF709F4BB722 Q35047301-86287FB3-267A-40CD-B405-B7539189D487 Q35119764-1BA79FA7-167D-4672-B524-C2109E1D301E Q35138682-71B71C5A-2EB6-4392-87E0-605F65E2B83F Q35207606-B7479C68-2979-4B34-A672-21602E2EF230 Q35741989-3E55BBD5-B70A-40FD-9158-BD21B68BE0B7 Q35986733-2FC0CB6F-6435-4D33-9F58-DC0B69E08685 Q36682576-DA39E320-8C15-412A-9DFB-7D22AA666F38 Q36700453-412E1585-E7ED-4E27-ACE6-AC32BE5C6360 Q36712429-CA07F02D-B41A-4CFE-B562-C4FD5E0BD678 Q37681950-45E65CB0-F3D3-4A92-B57F-F25C70A4BE73 Q37825528-7901AF6E-136E-4650-B1D1-17A18025AFF1 Q38000986-C0FA50BA-7D3F-4502-8E53-14F71139E42C Q38786910-D596B6C5-BEF1-495B-A513-1DF571EB1AE2 Q40410089-F5EDAF3B-4230-4314-8EE8-372C9A4FB3F2 Q40528471-7B9E5BE9-0BDF-404A-A09B-2BB825DA0073 Q42653980-E9428B2E-88C6-4D2E-98CB-FF2EA9B0A9D4 Q47548487-A796CD62-DD4F-4959-9AC3-1C2BB82882A1 Q50130388-C62718A2-3743-4F27-9829-609FDE47E669

P2860

Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE.

http://www.wikidata.org/entity/Q33870336

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE.

@ast

Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE.

@en

type

label

Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE.

@ast

Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE.

@en

prefLabel

Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE.

@ast

Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE.

@en

P1433

Q33870336-C4C12BF1-CA27-4364-8834-CFD05E11085E

P1476

Q33870336-EE57A29B-AA05-42D5-A773-29953C08CDA6

P2093

Q33870336-07BF7DED-6CEF-4C57-8D34-091199257D9B

Q33870336-1F290CF8-334F-4036-BAD4-9B8F049569B5

Q33870336-20948116-1138-47AA-A044-D7883D94858C

Q33870336-28E4BF6D-0D80-4E99-BF5F-09A69B80FA5A

Q33870336-996F62AE-E1A9-44A3-86EF-08742E091946

Q33870336-D16C97EB-2E6B-4961-8DCE-7FC3BDDD8CEC

Q33870336-F5207744-C010-489D-8F3F-A0305283DA03

P2860

Q33870336-035CC209-6172-4639-8DBB-2B381C53E042

Q33870336-0384C501-5FE3-4260-AED0-544C3C9950EF

Q33870336-04D9E8DC-27B0-4A55-83FF-BDEF78B57772

Q33870336-0A0F6C4E-1068-4D20-859D-66107B21B753

Q33870336-0E6F0247-2B57-4833-8F6C-7738DDBFEBBB

Q33870336-0ED8026F-D63C-4B75-98C9-E412C5545645

Q33870336-1011AE34-EC47-4808-8C04-EFCCD348C4C1

Q33870336-137C1266-5C28-41AB-94A9-5D049FE86CB4

Q33870336-1D0AE043-6206-4EB9-BF27-2B4B9A3D483F

Q33870336-1D44AD08-0380-41DF-AC6E-3F126795E93B

P304

Q33870336-18DB261A-21BD-405A-B25C-22C171DA5FEE

P31

Q33870336-782F5298-591F-4EFA-B576-16C813011753

P356

Q33870336-77BE3D43-5F34-4603-9120-B16DE027FEDB

P407

Q33870336-025F73D3-9C6A-411E-AEF1-FA2410FD90B2

P433

Q33870336-4CA506C4-1E74-4D07-9B4A-CDEFCF53CE3D

P478

Q33870336-A4378349-B611-483F-A90F-E716C6AD348D

P50

Q33870336-31168704-DFEF-420A-85E6-E435646367C0

Q33870336-324B982D-11CB-4C26-8F24-6D16EC5985FE

Q33870336-EF04E49B-996E-4C7B-9F48-B6DEDA170271

P577

Q33870336-0AF12B35-233C-4E43-AFB2-D7D0DEDBE6EE

P5875

Q33870336-003A195E-6763-4EF2-A7A3-988950B0F575

P698

Q33870336-298AA18D-CF92-415D-A8B5-43CA44F0509E

P921

Q33870336-C543DD25-5D4E-4ABF-BA4A-18B4884E5E32

P932

Q33870336-2DD2976E-BA61-43ED-8494-C27CEEFB2BA0

P356

J.VACCINE.2010.02.089

P1433

P1476

Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE.

@en

P2093

Geraldo Pedral-Sampaio

http://www.w3.org/2001/XMLSchema#string

Jeffrey Guderian

http://www.w3.org/2001/XMLSchema#string

Joelma Trigo

http://www.w3.org/2001/XMLSchema#string

Maria Nakatani

http://www.w3.org/2001/XMLSchema#string

Melissa Abbehusen

http://www.w3.org/2001/XMLSchema#string

Randall F Howard

http://www.w3.org/2001/XMLSchema#string

Robson Silva de Jesus

http://www.w3.org/2001/XMLSchema#string

P2860

Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy

Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator

Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.

Distinct antigen recognition pattern during zoonotic visceral leishmaniasis in humans and dogs.

Chemotherapy of canine leishmaniosis.

Canine leishmaniasis: epidemiological risk and the experimental model.

Canine leishmaniasis: novel strategies for control.

Development of a leishmaniasis vaccine: the importance of MPL.

Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum

P304

3333-3340

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2010.02.089

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41807308

http://www.w3.org/2001/XMLSchema#string

P698

20206667

http://www.w3.org/2001/XMLSchema#string

P921

visceral leishmaniasis

P932

2874835

http://www.w3.org/2001/XMLSchema#string